View source for Frequentist and Bayesian approaches

= Frequentist vs Bayesian approaches in trials =

Statistical methods play a central role in the design, [[analysis]], and interpretation of randomized controlled trials (RCTs). Two major frameworks—'''Frequentist''' and '''Bayesian'''—offer different approaches to understanding uncertainty and making inferences from data. While both are scientifically rigorous, they differ in how they define probability, handle prior information, and guide decision-making. Understanding their differences is essential for trialists, statisticians, and regulators when choosing the right method for a given research context.

== Frequentist Approach ==

The Frequentist framework is the traditional and most widely used approach in randomized controlled trials (RCTs). In this framework, probability is defined as the long-run frequency of an event occurring across repeated trials. '''[[Hypothesis|Hypothesis testing]]''' focuses on evaluating the null [[hypothesis]] (H₀), which usually assumes no effect. Researchers rely on '''p-values and confidence intervals''' to determine whether the observed results are statistically significant.

Frequentist analysis does not incorporate '''prior knowledge or external information'''. Instead, it draws inferences solely from the data collected within the trial. Common statistical methods used in this approach include t-tests, chi-square tests, ANOVA, Kaplan-Meier survival analysis, Cox proportional hazards models, and various forms of regression analysis.

Interpretation of results involves assessing whether the p-value falls below a pre-specified threshold (typically 0.05), suggesting statistical significance and prompting rejection of the null hypothesis. Confidence intervals are also used to estimate a plausible range for the treatment effect, assuming no prior information is available.

The Frequentist approach has several strengths. It is well-established, widely taught, and familiar to regulatory agencies like the FDA and EMA. Additionally, it avoids the subjectivity associated with prior distributions. However, it also has limitations. It cannot directly incorporate external evidence, p-values are often misinterpreted, and the fixed-sample design may limit flexibility for adaptive or interim decision-making.

== Bayesian Approach ==

The Bayesian framework offers a different perspective on statistical inference by defining probability as a measure of belief or certainty, which can be updated as new data become available. This approach combines '''prior information (known as the prior distribution)''' with observed trial data (likelihood) to generate a '''posterior distribution''', which reflects updated beliefs about the treatment effect.

Bayesian analysis allows researchers to make direct probability statements, such as “There is a 92% probability that the treatment reduces mortality.” This makes the interpretation of results more intuitive, especially for clinical decision-making. It also lends itself naturally to adaptive trial designs and interim analyses, where accumulating data can inform ongoing decisions.

Key components of Bayesian analysis include the '''prior distribution (representing pre-trial assumptions or evidence)''', the '''likelihood (based on observed data)''', and the '''posterior distribution (the updated inference)'''. Thresholds for decision-making—such as declaring treatment success when the posterior probability of benefit exceeds 95%—are clearly defined.

The Bayesian approach allows for the integration of external evidence and supports flexible, adaptive designs. It is particularly useful in settings with existing data or where rapid decision-making is important. However, it may introduce subjectivity through the selection of priors and is less familiar to many clinicians and trialists. Regulatory acceptance is growing but still evolving.

== Comparison Table ==

{| class="wikitable"
! Feature !! Frequentist !! Bayesian
|-
| Probability definition || Long-run frequency || Degree of belief (updated with data)
|-
| Use of prior information || No || Yes
|-
| Hypothesis testing || Null vs alternative using p-values || Posterior probabilities
|-
| Interim analysis || Requires correction for multiple looks || Naturally incorporated
|-
| Interpretation || Indirect (e.g., reject or fail to reject H₀) || Direct probability of effect
|-
| Flexibility || Fixed [[sample size]] || Supports adaptive designs
|-
| Regulatory familiarity || High (traditional standard) || Increasing acceptance
|}

----

=== Bibliography ===

# Berry DA. Bayesian clinical trials. ''Nature Reviews Drug Discovery''. 2006;5(1):27–36.
# Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley; 2004.
# Piantadosi S. Clinical Trials: A Methodologic Perspective. 3rd ed. Wiley; 2017. Chapter 20: Bayesian and decision-theoretic methods.
# FDA. Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. U.S. Food and Drug Administration; 2010. Available from: https://www.fda.gov
# Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. ''International Journal of Epidemiology''. 2006;35(3):765–775.
# Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. ''Annals of Internal Medicine''. 1999;130(12):995–1004.

----
''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''